Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

ARCH Venture Partners

Investor type Venture Capital
Founders Clinton Bybee Keith Crandell Robert Nelsen Steven Lazarus

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 420
Average round size
info
The average size of a deal this fund participated in
$54M
Portfolio companies 218
Rounds per year 11.67
Lead investments 47
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.48
Exits 87
Key employees 6
Stages of investment
Early Stage Venture
Seed

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

In 1986 was created ARCH Venture Partners, which is appeared as VC. The leading representative office of defined VC is situated in the Chicago. The venture was found in North America in United States.

The fund was created by Clinton W. Bybee, Keith L. Crandell, Robert Nelsen, Steven Lazarus. We also calculated 6 valuable employees in our database.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the ARCH Venture Partners, startups are often financed by Lux Capital, In-Q-Tel, Alexandria Real Estate Equities. The meaningful sponsors for the fund in investment in the same round are Wellcome Trust, Third Rock Ventures, Sofinnova Investments. In the next rounds fund is usually obtained by Wellcome Trust, Versant Ventures, Lux Capital.

The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. We can highlight the next thriving fund investment areas, such as Software, Medical. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the various public portfolio startups of the fund, we may underline Juno Therapeutics, Receptos, GRAIL Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund.

The fund is constantly included in 7-12 investment rounds annually. The higher amount of exits for fund were in 2015. When the investment is from ARCH Venture Partners the average startup value is 50-100 millions dollars. This ARCH Venture Partners works on 7 percentage points less the average amount of lead investments comparing to the other organizations. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 10 - 50 millions dollars. The real fund results show that this VC is 0 percentage points less often commits exit comparing to other companies.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of ARCH Venture Partners:
Typical Co-investors
ARCH Venture Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after ARCH Venture Partners:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Human Immunology Biosciences

Biotechnology
Life Science
Medical
Product Research
Therapeutics
$120M01 Nov 2022 San Francisco, California, United States

Neumora Therapeutics

Biotechnology
Health Care
Medical
$112M11 Oct 2022 Watertown, Massachusetts, United States

Rippl Care

Health Care
$32M28 Sep 2022 Seattle, Washington, United States

Pretzel Therapeutics

Biotechnology
Pharmaceutical
Therapeutics
$72M12 Sep 2022 Waltham, Massachusetts, United States

Autobahn Therapeutics

Biotechnology
Health Care
Life Science
Therapeutics
$32M08 Sep 2022 San Diego, California, United States

Orbital Therapeutics

Biotechnology
07 Sep 2022 -

Elephas Biosciences

Health Care
Medical
Medical Device
$41M06 Sep 2022 Madison, Wisconsin, United States

Vilya

Biotechnology
Health Diagnostics
Life Science
Medical
$50M29 Aug 2022 Seattle, Washington, United States

Happy Health

Health Care
$60M24 Aug 2022 Austin, Texas, United States
News
Founded last year, Mozart Therapeutics lands $55M to develop therapies for celiac and other diseases

– Mozart Therapeutics, a Seattle-based biotech startup, raised $55m funding.
– The round was led by ARCH Venture Partners along with Sofinnova Partners.
– Other backers include MRL Ventures Fund from Merck, Leaps by Bayer, and Eli Lilly & Company.

Recuro Health Raises $15M in Series A Funding

– Recuro Health is a Dallas, TX-based integrated digital health solutions company.
– Company raised $15m in Series A funding.
– The round was led by ARCH Venture Partners, with participation from OLSF Ventures, Cortado Ventures, 1843 Capital and Sage Venture Partners.
– The new investment will be used to execute the company’s ongoing acquisition and expanded marketing strategy, as well as to further build upon growth since the launch in March 2021.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent ARCH Venture Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: